Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-1101 in Chronic Painful Lumbosacral Radiculopathy
NCT07264270Phase 1Recruiting
- Sponsor
- Consano Bio
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of C-1101 in lumbosacral radiculopathy (3 cohorts), sponsored by Consano Bio. Primary endpoints: Treatment Emergent Adverse Events at 24 weeks and Adverse Events of Special Interest at 24 weeks. Started Dec 2025; status: recruiting.
02
Drugs
C-1101
03
Conditions
lumbosacral radiculopathy
Beyond the preview
Go deeper on NCT07264270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264270.